Tuberc Respir Dis Search


Tuberc Respir Dis > Volume 65(2); 2008 > Article
Tuberculosis and Respiratory Diseases 2008;65(2):142-146.
DOI:    Published online August 1, 2008.
Acute Respiratory Distress Syndrome after Topotecan Therapy in a Patient with Small Cell Lung Cancer.
Jung Hyun Tae, , Jin Hwa Lee, , Yoon Kyung Kim, , Yun Su Sim, , Kyung Jong Lee, , Young Wook Noh, , Jae Jung Park, , Yon Ju Ryu, , Eun Mi Chun, , Jung Hyun Chang,
1Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea.
2Department of Radiology, Ewha Womans University School of Medicine, Seoul, Korea.
Small cell lung cancer is characterized by an aggressive clinical course and a high tendency for early dissemination in spite of a good chemotherapy response. Topotecan is a topoisomerase I inhibitor, and it is used as second-line treatment for small cell lung cancer. The reported dose-limiting adverse reactions to topotecan are mainly hematologic. Yet pulmonary toxicity associated with topotecan is known to be rare. We report here on a case that showed the development of acute respiratory distress syndrome during the 3rd cycle of topotecan chemotherapy in a patient with small cell lung cancer. He developed dyspnea and respiratory failure, and the chest CT scan revealed diffuse ground-glass opacity that was probably due to chemotherapy-related pulmonary toxicity. He finally died of acute respiratory distress syndrome.
Key Words: Small cell carcinoma, Topotecan, Acute respiratory distress syndrome

Article category

Browse all articles >


Browse all articles >

Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail:                

Copyright © 2020 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2community

Close layer
prev next